Please login to the form below

Not currently logged in
Email:
Password:

Ranbaxy wins approval for generic analgesics

India-headquartered Ranbaxy Pharmaceuticals (RPI) has won FDA approval to manufacture and market two analgesic drugs.

India-headquartered Ranbaxy Pharmaceuticals (RPI) has won FDA approval to manufacture and market two analgesic drugs.

The FDA approval permits Ranbaxy to produce different dosages of hydrocodone bitartrate and acetaminophen for the treatment of moderate to moderately severe pain.

The approved drugs are bio-equivalent copies of Norco, Vicodin and Lortab, the annual market sales of which were USD 391m.

Jim Meehan, vice-president of sales and marketing for RPI, said: "These approvals further expand our product portfolio of affordable generic alternatives and will be launched in a November 2007 time period."

21st August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics